Find Practice Guidelines
The HIV Medicine Association is an organization of medical professionals who practice HIV medicine. We represent the interests of our patients by promoting quality in HIV care and by advocating for policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice.
IDSA Leads Stakeholders In Support of R&D Tax Credit for Antibiotics and Rapid Diagnostics
Forty groups representing providers, patients, public health and industry joined a letter – circulated by IDSA – supporting the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 3539.
IDSA Statement: White House Antibiotic Stewardship Forum
At this week’s White House Forum on Stewardship, IDSA President Steve Calderwood, MD, FIDSA said, “Our expertise on diagnosing and treating patients with serious infectious diseases makes us particularly well suited to lead multi-disciplinary institution-level stewardship programs that will improve patient outcomes”
Senators Urged to Support Antibiotic R&D Bill
A bill to establish a new FDA approval pathway for antibacterial drugs to treat life-threatening infections where there exists an unmet medical need has been introduced in the Senate. IDSA members asked to engage their Senators.
IDSA Spearheads Advocacy Effort for AR Funding
IDSA was joined by 56 groups in a letter to congressional appropriators calling for funding to address antimicrobial resistance.
Better Tests, Better Care: The Promise of Next Generation Diagnostics
This report for policymakers highlights the need for new diagnostics and recommends policies to stimulate diagnostics R&D and clinical integration.
IDSA, PIDS, and HIVMA Comments on NIH Physician-Scientist Workforce Report
IDSA, along with PIDS and HIVMA, jointly commented on the NIH Physician-Scientist Workforce Working Group report highlighting recommendations to improve the state of the physician-scientist workforce.
IDSA President Provides Testimony on the Need for New Antibiotics
On September 19th,
IDSA President Barbara Murray provided testimony to the Health Subcommittee of
the House Energy & Commerce Committee on the need for a coordinated federal
strategy to spur research and development for new antibiotics.
Tell Congress #CutsHurt!
Your help is needed to send a strong message to Congress that federal agency and program funding levels need to be finalized in the weeks ahead, so that new cuts are not set into motion.
1 of 8
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
Nontuberculous Mycobacterium Infections Associated with Heater-Cooler Devices
CDC/FDA Health Update about Immediate Need for Healthcare Facilities to Review Procedures for Cleaning, Disinfecting, and Sterilizing Reusable Medical Devices
US Compounding, Inc. Issues Voluntary Nationwide Recall of All Sterile Compounded Products
>> Read More
Two new studies in CID suggest that statins may hinder the body’s immune response and flu vaccine effectiveness in seniors.
According to the guidance, successful hepatitis C treatment results in sustained virologic response—or virologic cure—and thus would benefit nearly all of those chronically infected with HCV. Previously, the panel of experts who write the guidance had prioritized treatment with the direct-acting anti-virals for those with the greatest need, particularly those with severe liver disease.
From the PresidentTax Credit Bill IntroducedIncrease in Drug PriceJournal Club
A new study in CID suggests seniors are less likely to be diagnosed with flu-related illness in areas where more adults under 65 are immunized.
HCV has updated several sections of the website based on newly available therapies and data.
From the PresidentIDSA Compensation SurveyVote in Board ElectionsJournal Club
HIVMA applauds the release of the 2015 to 2020 National HIV/AIDS Strategy.
1 of 7
| IDSA | Contact Us
© Copyright HIVMA 2012 HIV Medicine Association